Latest news and articles about obesity medications from NEX English
Novo Nordisk has announced new study results confirming that high-dose Wegovy injections help patients lose nearly 28% of their weight over 72 weeks. This announcement follows the launch of the new dosage in the United States just a month ago.
A recent study has revealed that specific genes play a crucial role in the success of weight loss injections like Wegovy and Mounjaro, with varying results and side effects among individuals. This highlights the importance of genetic factors in weight management treatments.
Novo Nordisk has announced the launch of a new high-dose GLP-1 injection for obesity treatment, priced $50 lower than its competitor Zepbound. This release comes amid increasing competition in the obesity medication market.
Novo Nordisk announced that Wegovy pills demonstrated superior weight loss results compared to Eli Lilly's Foundayo pills. This highlights the competitive landscape of obesity medications.